Advanced delivery technologies provider Catalent has agreed to supply vial filling and packaging capacity to pharmaceutical company AstraZeneca.

As part of this agreement, the company’s Biologics unit will increase the capacity at the Anagni production facility located in Italy.

In the next few months, the 28,000m² facility will be prepared to support the large-scale commercial supply of the University of Oxford’s adenovirus vector based Covid-19 vaccine candidate, AZD1222.

Catalent president and chief operating officer Alessandro Maselli said: “Catalent has significant experience in the tech transfer and rapid scale-up of vaccine programmes to meet demand.

“Our manufacturing site in Anagni, Italy has served for many years as a primary launch facility for new medicines, and the plant’s skilled team will take great pride in preparing to manufacture this vaccine candidate for Covid-19 and ensuring that the product will be able to reach patients as quickly as possible if approved.”

Several hundreds of millions of doses of the vaccine candidate will be supplied from August this year. It is expected to run through to March 2022.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Catalent’s Anagni facility offers extensive capabilities in aseptic liquid filling for biologics and sterile products across multiple vial sizes.

It also provides primary and secondary packaging solutions, such as serialisation for product launches of oral solids, sterile, and biologics products.

Catalent’s Biologics also operates sterile drug product manufacturing and packaging facilities in Brussels, Belgium and Bloomington, Indiana.